Aktieanalyser | Från 10+ populära analyshus

Senaste aktieanalyserna

Analys | Redeye

• 27 Mar 11:11

Prostatype Genomics: Support from funding and published clinical studies - Redeye

Prostatype Genomics

Analys | Analysguiden

• 27 Mar 09:51

Railcare Group: Andhämtningspaus - Analysguiden

Rörelsemarginalen pressades under Q4 och bolaget står inför ökade investeringar.

Railcare

Analys | Analysguiden

• 27 Mar 09:40

Divio Technologies: Växande konsultintäkter och en stabil kassaposition - Analysguiden

Divio halverade rörelseförlusten under Q4. Kostnadskostymen sitter bra...

Divio Technologies

Analys | Analysguiden

• 27 Mar 09:40

Arcede Pharma: Prekliniska arbetet fortgår - Analysguiden

Arcede har levererat viktiga framsteg kring kandidaten RCD405 mot prim...

Arcede Pharma

Analys | Redeye

• 27 Mar 08:58

Smart Eye: Obstacles gone for those daring to be long-term investors - Redeye

Redeye thinks that with the rights issue completed, Smart Eye is now set to start its revenue accele...

Smart Eye

Analys | Nordea

• 27 Mar 08:55

NoHo Partners: Becomes market leader in the Helsinki entertainment and nightclub market through acquisition - Nordea

NoHo Partners has signed an agreement in which ownership of three nightclubs in Helsinki downtown wi...

NoHo Partners

Analys | Redeye

• 27 Mar 08:50

Klaria Pharma Holding: A punch in the face for migraines - Redeye

Klaria Pharma

Analys | Redeye

• 27 Mar 08:49

Better Collective: Key takes from capital markets day - Redeye

Redeye comments on Better Collective’s capital markets day giving our key takes on the event where t...

Better Collective

Analys | Redeye

• 24 Mar 14:24

Enzymatica: Comments on Plos One’s study investigation - Redeye

Redeye has noted Dagens Medicin’s article and Plos One’s investigation...

Enzymatica

Analys | Redeye

• 24 Mar 10:57

Lipum Q4 report: Focus on clinical progress - Redeye

Redeye provides a research update on Lipum following the Q4 report pub...

Lipum

Analys | Redeye

• 24 Mar 09:01

Flexion Mobile: Too Big to Ignore - Redeye

Redeye updates its view on Flexion Mobile following its strong Q4 2022 report released on March 22.

Flexion Mobile

Analys | Evli

• 24 Mar 08:04

Administer: Growth in place, profitability up next - Evli

Administer reports its H2/2022 results on March 30th.

Administer

Analys | Redeye

• 23 Mar 09:53

Q-linea: A targeted ASTar launch strategy - Redeye

Q-Linea

Analys | Redeye

• 23 Mar 08:49

Smart Eye: Study presented predicting worldwide DMS adoption – should support positive cash flow in H2 2024 - Redeye

Redeye thinks the presented study of global and European DMS adoption supports Smart Eye becoming ca...

Smart Eye

Analys | Mangold

• 23 Mar 08:03

Alzinova: Ny Alzheimerkandidat stormar fram - Mangold

För Alzinova stundar en spännande period då ny interimdata från Alzhei...

Alzinova

Analys | Nordea

• 23 Mar 07:57

Rovio: Concludes takeover discussions with Playtika, but continues the strategy review - Nordea

Rovio’s Board of Directors today confirmed that the preliminary discus...

Rovio

Analys | Redeye

• 22 Mar 16:05

Faron Pharmaceuticals: Positive FDA Feedback on Bexmarilimab - Redeye

Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for ...

Faron Pharmaceuticals

Analys | Analysguiden

• 22 Mar 15:12

QuiaPEG Pharmaceuticals: Intensifierat arbete inom affärsutveckling - Analysguiden

Ökat fokus på affärsutveckling under 2022 och flera pågående diskussioner för licensavtal.

QuiaPEG Pharmaceuticals

Analys | Edison

• 22 Mar 14:33

CoinShares International: En troligen fördelaktig överlevare av “kryptovintern” - Edison

CoinShares

Analys | Analyst Group

• 22 Mar 14:01

Eevia Health: Getting Closer to Black Numbers after Operating Improvements - Analyst Group

Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...

Eevia Health

Analys | Redeye

• 22 Mar 09:37

Alligator Bioscience: Rights Issue Announced– We Pause Our Coverage - Redeye

Redeye gives a short comment on the announced rights issue and pauses ...

Alligator Bioscience

Analys | ABG Sundal Collier

• 22 Mar 09:05

Ovzon: Inconvenient, but not a catastrophe - ABG

2022 EBIT impacted by bad debt provisions of SEK 34m The provision rel...

Ovzon

Analys | Redeye

• 22 Mar 08:25

Flexion Mobile Q4 2022: Strong growth in a challenging market - Redeye

Redeye comments on Flexion Mobiles Q4 2022 report. Strong revenue growth of 108% y/y, despite a chal...

Flexion Mobile

Analys | Redeye

• 22 Mar 07:38

Zwipe: Decent subscription rate - Redeye

Redeye comments on the outcome of Zwipe’s rights issue, which was subscribed to just below 69%.

Zwipe

Analys | ABG Sundal Collier

• 22 Mar 07:37

Alcadon: Raises capital to meet high demand - ABG

Alcadon Group

Analys | Analyst Group

• 21 Mar 11:24

AcuCort: Tar kliv i Norden mot kommersialisering i närtid - Analyst Group

AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit godkännande inom samtliga nordiska länder för Bo...

AcuCort

Analys | Analyst Group

• 21 Mar 11:16

Analyst Group Comments on OrderYOYO's Annual Report 2022

OrderYOYO published, March 20, the company’s annual report of 2022, an...

Analys | Penser

• 21 Mar 11:02

Talkpool: In i 2023 med fokus på marginaler och kassaflöden - Penser

Växer starkt och kommunicerar lönsamhetsfokus Talkpool redovisar intäk...

Talkpool

Analys | Redeye

• 21 Mar 10:37

Wyld Networks: Plan to expand into NB-IoT/5G - Redeye

Redeye responds to Wyld’s press release from today, revealing the company’s intention to upgrade its...

Wyld Networks

Analys | ABG Sundal Collier

• 21 Mar 09:34

Careium: Set for positive FCF in Q1 - ABG

5% Q1e adj. EBITA margin and 7% org. growth Limited adj.

Careium

Föregående Nästa

Börskollen

För dig med koll på börsen

Senaste aktieanalyserna

Prostatype Genomics: Support from funding and published clinical studies - Redeye

Railcare Group: Andhämtningspaus - Analysguiden

Divio Technologies: Växande konsultintäkter och en stabil kassaposition - Analysguiden

Arcede Pharma: Prekliniska arbetet fortgår - Analysguiden

Smart Eye: Obstacles gone for those daring to be long-term investors - Redeye

NoHo Partners: Becomes market leader in the Helsinki entertainment and nightclub market through acquisition - Nordea

Klaria Pharma Holding: A punch in the face for migraines - Redeye

Better Collective: Key takes from capital markets day - Redeye

Enzymatica: Comments on Plos One’s study investigation - Redeye

Lipum Q4 report: Focus on clinical progress - Redeye

Flexion Mobile: Too Big to Ignore - Redeye

Administer: Growth in place, profitability up next - Evli

Q-linea: A targeted ASTar launch strategy - Redeye

Smart Eye: Study presented predicting worldwide DMS adoption – should support positive cash flow in H2 2024 - Redeye

Alzinova: Ny Alzheimerkandidat stormar fram - Mangold

Rovio: Concludes takeover discussions with Playtika, but continues the strategy review - Nordea

Faron Pharmaceuticals: Positive FDA Feedback on Bexmarilimab - Redeye

QuiaPEG Pharmaceuticals: Intensifierat arbete inom affärsutveckling - Analysguiden

CoinShares International: En troligen fördelaktig överlevare av “kryptovintern” - Edison

Eevia Health: Getting Closer to Black Numbers after Operating Improvements - Analyst Group

Alligator Bioscience: Rights Issue Announced– We Pause Our Coverage - Redeye

Ovzon: Inconvenient, but not a catastrophe - ABG

Flexion Mobile Q4 2022: Strong growth in a challenging market - Redeye

Zwipe: Decent subscription rate - Redeye

Alcadon: Raises capital to meet high demand - ABG

AcuCort: Tar kliv i Norden mot kommersialisering i närtid - Analyst Group

Analyst Group Comments on OrderYOYO's Annual Report 2022

Talkpool: In i 2023 med fokus på marginaler och kassaflöden - Penser

Wyld Networks: Plan to expand into NB-IoT/5G - Redeye

Careium: Set for positive FCF in Q1 - ABG